Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Study identifier:D933AC00005

ClinicalTrials.gov identifier:NCT05835778

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Specific use-results study of IMFINZI Intravenous Infusion 120 mg,500mg in patients with Curatively unresectable biliary tract cancer

Medical condition

biliary tract cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 07 Jun 2023
Estimated Primary Completion Date: 16 Nov 2025
Estimated Study Completion Date: 16 Nov 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria